Skip to content

Efficacy of personalized embryo transfer based on endometrial receptivity test in patients with polycystic ovarian syndrome (PCOS)

Efficacy of personalized embryo transfer based on endometrial receptivity test in patients with polycystic ovarian syndrome (PCOS)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064131
Enrollment
Unknown
Registered
2022-09-27
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome

Interventions

Experimental group:receiving personalized embryo transfer based on endometrial receptivity test
Control group:Receiving conventional embryo transfer

Sponsors

Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with PCOS according to 2003 Rotterdam criteria; 2. Aged 20-35 years; 3. Having 2 or more good-quality frozen embryos; 4. Willing to join the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Accompany with endometrial diseases, including intrauterine adhesions, endometrial tuberculosis, atypical endometrial hyperplasia, untreated endometrial polyps or endometritis, etc.; 2. Accompany with uterine diseases, including uterine malformation, uterine mediastinum, intramural fibroids compressing the uterine cavity line, etc.; 3. Untreated severe hydrosalpinx; 4. Stage III-IV endometriosis; 5. Accompaned with other diseases that affect embryo implantation, such as prethrombotic state, immune system diseases (systemic lupus erythematosus, Sjgren's syndrome, etc.), malignant tumors, uncontrolled diabetes, hypertension, etc.; 6. Patients with repeated implantation failure, defined as have received 2 or more embryo transfers cycles, transferred 2 high-quality blastocysts or 4 high-quality cleavage-stage embryos without pregnancy; 7. Patients who have undergone ovarian wedge resection or ovarian drilling; 8. Patients who have used androgen inhibitors, contraceptives, etc. in the past 3 months; 9. Patients with recurrent miscarriage, defined as having experienced 3 or more pregnancy losses (including biochemical pregnancy); 10. Other factors that researchers consider unsuitable to participate in this study, such as mental factors, etc.

Design outcomes

Primary

MeasureTime frame
Intrauterine clinical pregnancy rate;

Secondary

MeasureTime frame
Biochemical pregnancy rate;Embryo implantation rate;Ongoing clinical pregnancy rate;Live birth rate;Ectopic pregnancy rate;Miscarriage rate;Multiple pregnancy rate;

Countries

China

Contacts

Public ContactLi Yanping

Xiangya Hospital, Central South University

liyanp@csu.edu.cn13607317798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026